abstract |
The present disclosure relates to pharmaceutically acceptable salts and crystalline forms thereof, of compound 1 which is (S) -2-(4-chloro-3-(l-(difluoromethyl)-lH-l,2,4-triazol-5-yl)phenyl)-2- ((R)-4-(4-(2-cyclopropyl-2H-l,2,3-triazol-4-yl)phenyl)-2-imino-5- oxo-4-(3, 3, 3-trifluoro-2, 2-dimethyl propyl) imidazolidin-l-yl)ethyl (l-(difluoromethyl)cyclopropyl)carbamate, which is useful in the treatment of a Retroviridaeviral infection including an infection caused by the HIV virus. |